Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
tofacitinib
i
Other names:
CP-690,550, CP-690550, CP690550
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Generic mfg.
Drug class:
JAK2 inhibitor, JAK1 inhibitor, JAK3 inhibitor
Related drugs:
‹
entrectinib (178)
ruxolitinib (73)
AZD1480 (5)
CHZ868 (4)
pacritinib (3)
CEP-701 (3)
AZ 960 (2)
fedratinib (2)
momelotinib (2)
JSI-124 (2)
TG02 (2)
EC-70124 (1)
FAK-JAK 2 dual Inhib (0)
R 723 (0)
TG101209 (0)
flonoltinib (0)
LY 2784544 (0)
BS-HH-002.SA (0)
AG 490 (0)
DZD4205 (1)
INCB039110 (1)
INCB052793 (0)
SHR0302 (0)
ritlecitinib (0)
entrectinib (178)
ruxolitinib (73)
AZD1480 (5)
CHZ868 (4)
pacritinib (3)
CEP-701 (3)
AZ 960 (2)
fedratinib (2)
momelotinib (2)
JSI-124 (2)
TG02 (2)
EC-70124 (1)
FAK-JAK 2 dual Inhib (0)
R 723 (0)
TG101209 (0)
flonoltinib (0)
LY 2784544 (0)
BS-HH-002.SA (0)
AG 490 (0)
DZD4205 (1)
INCB039110 (1)
INCB052793 (0)
SHR0302 (0)
ritlecitinib (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
JAK3 mutation
T Acute Lymphoblastic Leukemia
JAK3 mutation
T Acute Lymphoblastic Leukemia
tofacitinib
Resistant: C4 – Case Studies
tofacitinib
Resistant
:
C4
tofacitinib
Resistant: C4 – Case Studies
tofacitinib
Resistant
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login